Toxicology News and Research RSS Feed - Toxicology News and Research

Toxicology is the study of harmful interactions between chemical, physical, or biological agents and biological systems.
Non-invasive autopsy service nominated for national award

Non-invasive autopsy service nominated for national award

Sheffield’s radiology team are in the running for a top national medical award after establishing the world’s first minimally invasive autopsy service for babies and children who tragically die in the womb or 28 days after birth. [More]
NNI publishes report on nanotechnology environmental, health, and safety risk science status

NNI publishes report on nanotechnology environmental, health, and safety risk science status

The National Nanotechnology Initiative (NNI) today published the report from the workshop, "Stakeholder Perspectives on Perception, Assessment, and Management of the Potential Risks of Nanotechnology" (R3 Workshop), which was held September 10-11, 2013, in Washington, D.C. [More]
EHT expert paper raises important and unanswered questions about safety of wearable tech

EHT expert paper raises important and unanswered questions about safety of wearable tech

Wearable technology is raising health concerns worldwide. A recent New York Times article by Nick Bilton is raising important and unanswered questions about the safety of wearable tech, according to the non-profit research group, Environmental Health Trust. [More]
Study explores the efficacy of antivenom against copperhead snake bites

Study explores the efficacy of antivenom against copperhead snake bites

Dr. Spencer Greene wants to make sure the standard treatment for copperhead snake bites, the most common venomous snake in greater Houston and southeast Texas, works, and if it doesn't, he wants to stop its use. [More]
UZH researchers map spinal cord neurons involved in 'Gate Control Theory' of pain

UZH researchers map spinal cord neurons involved in 'Gate Control Theory' of pain

Sensing pain is extremely unpleasant and sometimes hard to bear - and pain can even become chronic. The perception of pain varies a lot depending on the context in which it is experienced. 50 years ago, neurobiologist Patrick Wall and psychologist Ronald Melzack formulated the so-called "Gate Control Theory" of pain. [More]
IU researchers reveal how Toxoplasma parasites modify brain cells

IU researchers reveal how Toxoplasma parasites modify brain cells

Rodents infected with a common parasite lose their fear of cats, resulting in easy meals for the felines. Now IU School of Medicine researchers have identified a new way the parasite may modify brain cells, possibly helping explain changes in the behavior of mice -- and humans. [More]
Gentronix signs three-year technology access deal with SIMM

Gentronix signs three-year technology access deal with SIMM

UK based Gentronix Limited, the specialist genetic toxicology company, today announced it has signed a three year technology access deal with one of China's most prestigious research intensive institutes, Shanghai Institute Materia Medica, Chinese Academy of Sciences. [More]
New study finds that fetus exposed to tobacco smoke faces diabetes risk in adulthood

New study finds that fetus exposed to tobacco smoke faces diabetes risk in adulthood

A fetus exposed to tobacco smoke may be at increased risk for diabetes in adulthood, a new study of adult daughters finds. [More]
SCIEX and Labor Berlin Collaboration to Advance Forensic Testing

SCIEX and Labor Berlin Collaboration to Advance Forensic Testing

SCIEX announced today a research collaboration with Labor Berlin, the largest clinical laboratory in Germany, for the development of a hybrid Quadrupole Time-of-Flight (TOF) MS/MS reference library of relevant forensic chemical compounds [More]
Existing drug could help treat MS, other neurological diseases

Existing drug could help treat MS, other neurological diseases

Damage to myelin, the fatty insulator that enables communication between nerve cells, characterizes multiple sclerosis (MS) and other devastating neurological diseases. [More]
Pharmacyclics completes toxicology studies of BTK inhibitor in RA

Pharmacyclics completes toxicology studies of BTK inhibitor in RA

Pharmacyclics, Inc. today announced that longer-term toxicology studies for its newly developed Bruton's tyrosine kinase (BTK) inhibitor for rheumatoid arthritis, or RA, have been completed. [More]
Palatin introduces clinical trial website in support of bremelanotide phase 3 study for FSD treatment

Palatin introduces clinical trial website in support of bremelanotide phase 3 study for FSD treatment

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has launched a clinical trial website in support of its phase 3 reconnect study with bremelanotide for the treatment of female sexual dysfunction (FSD). [More]
Doctoral students of Magicbullet network to develop 'gentle' cancer treatment

Doctoral students of Magicbullet network to develop 'gentle' cancer treatment

Medication that specifically targets cancer cells and delivers its active agent without harming healthy cells - this is what doctoral students of the Magicbullet network will be working on from mid-2015. Bielefeld University is coordinating the programme for the development of "gentle" cancer treatment. [More]
Nicotine metabolite supports learning, memory by amplifying action of primary chemical messenger

Nicotine metabolite supports learning, memory by amplifying action of primary chemical messenger

Nicotine's primary metabolite supports learning and memory by amplifying the action of a primary chemical messenger involved in both, researchers report. [More]

Psychemedics' revenue increases 4% to $6.8 million in fourth quarter 2014

Psychemedics Corporation today announced fourth quarter and year-end financial results for the period ended December 31, 2014. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of February 23, 2015 to be paid on March 6, 2015. This will be the Company's 74th consecutive quarterly dividend. [More]
Alere reports net revenue of $666.9 million for fourth quarter 2014

Alere reports net revenue of $666.9 million for fourth quarter 2014

Alere Inc., a global leader in rapid diagnostics, announced its financial results for the quarter ended December 31, 2014. [More]
Study shows that drinking green tea before taking supplements may reduce toxicity risk

Study shows that drinking green tea before taking supplements may reduce toxicity risk

As high doses of green tea extract supplements for weight loss become more popular, potential liver toxicity becomes a concern. In the last decade, dozens of people have been diagnosed with the condition. However, drinking green tea in the weeks before taking supplements likely reduces risk, according to researchers in Penn State's College of Agricultural Sciences. [More]
Cell-penetrating nanoparticles can efficiently transport oligonucleotide drugs into cells

Cell-penetrating nanoparticles can efficiently transport oligonucleotide drugs into cells

Therapeutic oligonucleotide analogs represent a new and promising family of drugs that act on nucleic acid targets such as RNA or DNA; however, their effectiveness has been limited due to difficulty crossing the cell membrane. [More]
Using Cultrex BME 2 reduced growth factor to enable long-term culture of human hepatocytes

Using Cultrex BME 2 reduced growth factor to enable long-term culture of human hepatocytes

AMSBIO reports on the recent publication in Cell [1] by Dr Meritxell Huch, Prof Hans Clevers et al. of ground-breaking research using Cultrex BME2 reduced growth factor (organoid growth matrix) to enable long-term (>1 year) culture of genome-stable bipotent stem cells from adult human liver. These results open up new experimental avenues towards the use of human liver material expanded in vitro as an alternative cell source for disease modeling, toxicology studies, drug testing, regenerative medicine and gene therapy. [More]
Genevac's new SampleGenie 4 for direct concentration of large sample volumes into vials

Genevac's new SampleGenie 4 for direct concentration of large sample volumes into vials

SampleGenie 4 is the latest version of Genevac’s unique technology for direct concentration of large sample volumes into vials, designed for use in the Rocket Synergy Evaporator. [More]
Advertisement
Advertisement